CN103405501A - Preparation method of three-component blood-activating and stasis-dissolving capsules - Google Patents
Preparation method of three-component blood-activating and stasis-dissolving capsules Download PDFInfo
- Publication number
- CN103405501A CN103405501A CN2013103482957A CN201310348295A CN103405501A CN 103405501 A CN103405501 A CN 103405501A CN 2013103482957 A CN2013103482957 A CN 2013103482957A CN 201310348295 A CN201310348295 A CN 201310348295A CN 103405501 A CN103405501 A CN 103405501A
- Authority
- CN
- China
- Prior art keywords
- capsules
- preparation
- flavor
- circulation promoting
- stasis dispelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A preparation method of three-component blood-activating and stasis-dissolving capsules relates to the technical field of medicines, particularly to an improvement on a processing method of the three-component blood-activating and stasis-dissolving capsules. With the following raw materials in parts by weight, the preparation method comprises the steps as follows: (1) extracting salvia miltiorrhiza, filtering and concentrating an extract, adding ethanol to the extract, stirring, standing, collecting supernatant fluid, recycling ethanol, drying and finely grinding; (2) taking leech and lumbricus, adding physiological salt, grinding to obtain homogenate, performing freeze-and-thaw extraction, performing filtration or centrifugation, filtering with an ultrafiltration membrane, concentrating to obtain thick paste, reducing viscosity, stirring uniformly, and drying; (3) mixing the extracts of salvia miltiorrhiza, lumbricus and leech, and obtaining the capsules. The capsules have the advantages of small size, convenience for taking, low price, high efficiency, small dosage, safety and effectiveness, are highly concentrated, have good homogeneity and controllability, are easy for a human body to absorb, are far smaller in dosage than the lowest dosage specified by pharmacopeia, can be used for a long term and can overcome the defect that like oral preparations are not suitable for long-term use.
Description
Technical field
The present invention relates to medical technical field, be specifically related to the improvement for three flavor blood circulation promoting and blood stasis dispelling capsule processing method.
Background technology
By the three flavor blood circulation promoting and blood stasis dispelling capsules that Radix Salviae Miltiorrhizae, Hirudo and Pheretima are made, function with cure mainly: blood circulation promoting and blood stasis dispelling, dredge the meridian passage.For the apoplexy apoplex involving the channels and collaterals due to obstruction of collaterals by blood stasis, disease is seen hemiplegia, crooked mouth and tongue, and speech is stuttering puckery or in silence, hemianesthesia, the body of the tongue purple is dim, or petechia or ecchymosis, deep and hesitant pulse are arranged; Cerebral infarction convalescent period is seen above-mentioned patient.Regulation in Chinese Pharmacopoeia 2010 editions: Radix Salviae Miltiorrhizae consumption 10～15 grams, Hirudo consumption 1～3 gram, Pheretima consumption 5～10 grams.There is the shortcoming that dosage is large, produce effects is slow in the medicament that traditional extraction process is extracted, and escalated dose is taken can strengthen toxic and side effects, has the drug safety problem.
Summary of the invention
Technical problem to be solved by this invention is: for the problems referred to above, provide a kind of improvement of three flavor blood circulation promoting and blood stasis dispelling capsule processing method, with the medication curative effect that improves three flavor capsules with take effect.
Technical solution of the present invention is: by weight, comprise the following steps:
(1), get 300～700 parts of Radix Salviae Miltiorrhizaes, add 12～24 times, water amount and extract, filter, be concentrated into the clear paste of relative density 1.0～1.5, add 2.4～4.8 times of amounts of ethanol, stir, standing 24～72 hours, get supernatant, reclaim ethanol and be dried to dry, porphyrize, standby;
(2), each 80～120 parts of water intaking trematodiasis, Pheretimas add respectively 1～10 times of amount normal saline and soak, and is ground into homogenate, freezes molten extraction, filters or centrifugal filtrate for later use; The residue extracting in water, filter, and filtrate merges with supernatant, and the ultrafilter membrane filtration is concentrated into the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirs, and is dried to dryly, and porphyrize is standby; The medical material residue soaked 1～10 day by 1～8 times of amount of ethanol again, filtered, and filtrate is concentrated into the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirs, be dried to dry, porphyrize, standby;
(3), Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract are merged, add 2～10 parts of micropowder silica gels, add starch to make into 200～400 parts, stir, incapsulate, obtain.
Technique effect of the present invention is: it has, and volume is little, taking convenience, cheap, produce effects is fast, taking dose is low, advantage safely and effectively, this product height is concentrated, the homogeneity of product and controllability are good, be beneficial to absorption of human body, using dosage is far smaller than the lowest dose level of pharmacopeia regulation, but long-term taking, and can overcome the weakness that similar oral formulations should not take for a long time.
The specific embodiment
The Main Ingredients and Appearance of three flavor blood circulation promoting and blood stasis dispelling capsules comprises Radix Salviae Miltiorrhizae, Hirudo and Pheretima, and concrete preparation method comprises the following steps:
(1), get 500 parts of Radix Salviae Miltiorrhizaes, add 12～24 times, water amount and extract, filter, be concentrated into the clear paste of relative density 1.0～1.5, add 2.4～4.8 times of amounts of ethanol, stir, standing 24～72 hours, get supernatant, reclaim ethanol and be dried to dry, porphyrize, standby;
(2), each 100 parts of water intaking trematodiasis, Pheretimas add respectively 1～10 times of amount normal saline and soak, and is ground into homogenate, freezes molten extraction, filters or centrifugal filtrate for later use; The residue extracting in water, filter, and filtrate and supernatant merge, and ultrafilter membrane filters, and filtrate low temperature (4 ℃～room temperature) is concentrated into the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirs, and cold drying is to dry, and porphyrize is standby; The medical material residue was measured warm macerating 1～10 day with 1～8 times of ethanol again, filtered, and the filtrate cryoconcentration is to the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirred, and cold drying is extremely dry, and porphyrize is standby;
(3), Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract are merged, add 2～10 parts of micropowder silica gels, add starch to make into 300 parts, stir, incapsulate, obtain.
In step (1), extracting in water is 2 times, adds 6～12 times of amounts of water at every turn, extracts 1～5 hour.Ethanol described in step (1) is for adding 1～6 times of amount of 80% ethanol.In step (1), mixing time is 10～50 minutes.In step (2), Hirudo, Pheretima add respectively the immersion of 1～10 times of amount normal saline, continue and add 2 times of amounts of normal saline, are ground into homogenate.After in step (2), being ground into homogenate, jolting was extracted 1～12 hour.Step is frozen molten extraction in (2), standing 1～12 hour.The middle residue of step (2) adds 1～5 times of amount of water and extracts respectively 2 times, each 1～3 hour.Step (2) Chinese crude drug residue is measured lixiviate 1～10 day with 1～8 times of 50% ethanol.
Specific embodiment:
Get red rooted salvia 500g, extracting in water 2 times adds 6～12 times of amounts of water at every turn, extracted 1～5 hour, and filtered merging filtrate, be concentrated into the clear paste of relative density 1.0～1.5, add 3～6 times of amounts of 80% ethanol, stirred standing 24～72 hours 50 minutes, get supernatant, reclaim ethanol and be dried to dry, porphyrize, standby.
Water intaking trematodiasis, each 100g medical material of Pheretima add respectively 1～5 times of amount normal saline and soak, and continuously add 2 times of amounts of normal saline, are ground into homogenate (jolting was extracted 3～12 hours), freeze molten extraction (standing 12 hours), filter or centrifugal filtrate for later use; Residue adds 1～5 times of amount of water and extracts respectively 2 times, and each 1～3 hour, filter, filtrate and supernatant merge, and the millipore ultrafilter membrane filters, and the filtrate cryoconcentration is to the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirs, and cold drying is to dry, and porphyrize is standby; The medical material residue was measured warm macerating 1～10 day with 1～8 times of 50% ethanol again, filtered, and the filtrate cryoconcentration is to the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirred, and cold drying is extremely dry, and porphyrize is standby.
Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract are merged, add micropowder silica gel 2～10g, add starch to make into 300g, stir, incapsulate, make 1000, obtain.
1. this product has following features:
1. low dosage
| The medical material title | 2010 editions pharmacopeia using dosages | This prescription using dosage |
| Radix Salviae Miltiorrhizae | 10～15 grams | 2 grams |
| Hirudo | 1～3 gram | 0.4 gram |
| Pheretima | 5～10 grams | 0.4 gram |
Regulation in this prescription Chinese crude drug using dosage, Chinese Pharmacopoeia 2010 editions: Radix Salviae Miltiorrhizae consumption 10～15 grams, Hirudo consumption 1～3 gram, Pheretima consumption 5～10 grams.The actual dose of this agent medical material is: Radix Salviae Miltiorrhizae 2 grams (pharmacopeia dosage 20%～13.3%), and Hirudo 0.4 gram (pharmacopeia dosage 40%～13.3%), Pheretima is 0.4 gram (pharmacopeia dosage 8%～4%), is far smaller than the lowest dose level of pharmacopeia regulation, therefore this agent safety.
2. extract at low temperature drying: adopt the modern Chinese medicine extractive technique, utilize freeze thawing technique, by the extract at low temperature drying, make the animal drug tissue disruption, its effective ingredient is leached, keep the active proteic substance in medical material, improve the bioavailability of this product.
3. the high speed centrifugation separation energy is removed the material that human body is difficult for absorbing and needing the absorbent high molecular of enzymolysis conversion, extracts the biological substance be dissolved down in medical material, is beneficial to absorption of human body, and onset time is fast.
4. water, alcohol extraction material merge use, more similar in appearance to the absorption of human body to whole medical materials.
5. this agent adopts state-of-the-art millipore membrane separation technique in the world to concentrate, and has guaranteed homogeneity and the controllability of product.
But 6. this agent long-term taking, the weakness that can avoid similar oral formulations to take for a long time.
2. the necessity of the reasonability of this product dosage form and clinical use
1. the reasonability of this kind dosage form: capsule has to be covered medicine and makes us uncomfortable bitterness and stink, makes that it is clean and tidy, attractive in appearance, easily swallows; Improve the bioavailability of medicine; Increase medicine stability.This kind adopts No. 0 Caplet, and highly concentrated, volume is little, and taking convenience only takes 2 at every turn, takes 2 every day, easy to carry, is easy to keeping.
2. the necessity of the clinical use of this kind
The curative effect advantage: with common chemicals, compare: as streptokinase, urokinase, heparin, A Sibilin etc., compare, these medicines are prone to the problems such as hemorrhage recurrence, and the administration inconvenience; With same disease class Chinese patent medicine, compare: huge with the veriety prescription, and effect is slowly.This prescription prescription keeps TCM Features, forms briefly, and drug effect is definite, and taking dose is low, safe and effective.
3. the isolation technics of this prescription process using, as low temperature, membrance concentration, water containing ethanol extraction share, viscosity reduction is thick, the technology such as cold drying, also do not find in same veriety.Extract temperature and change the temperature near human body into, make medicine change into the comprehensive active mixture that human body easily absorbs, so more meet the Chinese medical theory of determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.While is due to the reduction of single medical material using dosage in side, will cause product (safety/price) ratio higher, discussion by the nearly over thousands of article of single medical material in Gu, Modern Literature the other side, illustrate that this product is safe and effective, fully demonstrated the eternal principle of " safety, effective, economic, reasonable " this medicine development.
3. the economic benefit of this prescription
With the comparison of identical component kind is arranged in similar disease kind, this prescription Costco Wholesale is cheap 40%, simultaneously this kind rapid-action, have no side effect.
The present invention---three flavor blood circulation promoting and blood stasis dispelling capsule pharmacodynamics conclusion (of pressure testing)s
Positive control drug: Xueshuan Xinmaining capsule; The vincamine slow releasing capsule.
Three flavor capsules: 0.252g crude drug/kg(low dosage), in 0.504g crude drug/kg(), 1.008g crude drug/kg(is high);
1. the impact of three flavor Capsule in Rats middle cerebral artery embolic cerebral ischemic models;
Conclusion: with sham operated rats, compare, model control group cerebral ischemia area obviously increases, two groups compare the difference significance (
P<0.01).With model control group, compare, three flavor capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group cerebral ischemia area obviously reduces, the equal significance of difference (
P<0.05,
P<0.01,
P<0.05,
P<0.01).
2. the impact of three flavor Capsule in Rats models of cerebral ischemia-reperfusion injuries;
Conclusion: with sham operated rats, compare, model control group SOD vigor obviously reduces, and MDA, NO content obviously raise, two groups compare MDA, NO content difference significance (
P<0.01,
P<0.05).With model control group, compare, three flavor capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group SOD vigor obviously raises, the difference significance (
P<0.05,
P<0.05,
P<0.05); MDA, NO content obviously reduce, the difference significance (
P<0.05,
P<0.05,
P<0.05).
3. three flavor capsules are on mice broken end ischemia model frequency of respiration and the impact of breathing persistent period;
Conclusion: with model control group, compare, three flavor capsule 0.364g crude drug/kg, 0.728g crude drug/kg, the 1.456g crude drug/kg dosage group mice number of times showed increased of panting, the difference significance (
P<0.01,
P<0.01,
P<0.01); Three flavor capsule 0.728g crude drug/kg, 1.456g crude drug/kg dosage group, the XUESHUANXINMAINING 1.56g/kg dosage group mouse breathing persistent period obviously extends, the difference significance (
P<0.01,
P<0.05,
P<0.05).
4. three flavor capsule mice hypoxia endurance tests;
Conclusion: model control group is compared, three flavor capsule 0.364g crude drug/kg, 0.728g crude drug/kg, 1.456g crude drug/kg dosage group, XUESHUANXINMAINING 1.56g/kg dosage group, there is the effect trend of prolongation the vincamine slow releasing capsule 15.6mg/kg dosage group mouse survival time, but there was no significant difference (
P>0.05).
5. three flavor Capsule in Rats ligation postcava cause thrombotic impact;
Conclusion: compare with model control group, three flavor capsule 0.252g crude drug/kg, 0.504g crude drug/kg, 1.008g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group wet weight of thrombus obviously alleviates, the difference significance (
P<0.05,
P<0.05,
P<0.01,
P<0.05,
P<0.05); Three flavor capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group thrombosis dry weight obviously alleviates, the difference significance (
P<0.05,
P<0.01,
P<0.01,
P<0.05).
6. the impact of the total artery thrombosis of three flavor Capsule in Rats To Stimulation of Cervicals;
Conclusion: compare with model control group, three flavor capsule 0.504g crude drug/kg, 1.008g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, the average blocking rate that vincamine slow releasing capsule 10.8mg/kg dosage group carotid thrombus forms obviously reduces, the difference significance (
P<0.05,
P<0.01,
P<0.05,
P<0.05).
7. the impact of three flavor Capsule on Rabbit Platelets;
Conclusion: with the blank group, compare, three flavor capsule 0.524g crude drugs/kg dosage group platelet aggregation rate obviously reduces, the difference significance (
P<0.05).
8. the impact of the experimental blood stasis model hemorheological property of three flavor Capsule in Rats;
Conclusion: with the blank group, compare, the model control group whole blood viscosity obviously raises, erythrocyte aggregation index obviously raises, erythrocyte electrophoretic time obviously extends, the difference significance (
P<0.001).With model control group, compare, three flavor capsule 0.252g crude drug/kg, 0.504g crude drug/kg, 1.008g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group whole blood viscosity obviously reduces, the difference significance (
P<0.001,
P<0.001,
P<0.001,
P<0.001,
P<0.001), erythrocyte aggregation index obviously reduces, the difference significance (
P<0.001,
P<0.001,
P<0.001,
P<0.001,
P<0.001), erythrocyte electrophoretic time obviously shortens, the difference significance (
P<0.001,
P<0.001,
P<0.001,
P<0.001,
P<0.001).
9. the impact of three flavor capsules on the mice Mesentery microcirculation;
Conclusion: with the blank group, compare, three flavor capsule 1.456g crude drugs/kg dosage group average caliber when dripping Ard 2min, 8min obviously increases, the difference significance (
P<0.05,
P<0.05); With the blank group, compare, three flavor capsule 1.456g crude drugs/kg dosage group is before dripping Ard, three flavor capsule 0.364g crude drug/kg, 0.728g crude drug/kg, 1.456g crude drug/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group is when dripping Ard 2min, three flavor capsule 1.456g crude drugs/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group flow velocity when dripping Ard 8min is accelerated, the difference significance (
P<0.01,
P<0.01,
P<0.01,
P<0.001,
P<0.001,
P<0.001,
P<0.001,
P<0.00,
P<0.001); With the blank group, compare, three flavor capsule 1.456g crude drugs/kg dosage group, XUESHUANXINMAINING 1.08g/kg dosage group, vincamine slow releasing capsule 10.8mg/kg dosage group is when dripping Ard 2min, three flavor capsule 1.456g crude drugs/kg dosage group, the fluidised form scoring when dripping Ard 8min of XUESHUANXINMAINING 1.08g/kg dosage group increases, the difference significance (
P<0.01,
P<0.01,
P<0.01,
P<0.001,
P<0.001).
Conclusion: three flavor capsules have ischemia resisting, antithrombotic, antiplatelet aggregation, improve the blood flow change, improve microcirculatory effect, and cerebral infarction is had to protection and therapeutical effect.
The present invention---the acute toxicity test in mice research of three flavor blood circulation promoting and blood stasis dispelling capsules
Mice is with maximum administration concentration and maximum administration volume, and in 1 day, gastric infusion is 1 time, and dosage is 51.84g crude drug/kg, this dosage is about 1036 times (becoming body weight for humans by 60kg) of adult's oral dose every day, animal, without death, was observed 14 days, had no the overt toxicity reaction.Animal carries out gross anatomy after the observation period finishes, the main organs such as the perusal heart, liver, spleen, lung, kidney, and no abnormality seen changes.
The present invention---three flavor blood circulation promoting and blood stasis dispelling Capsules on Rats long term toxicity test research data and documents and materials
Three flavor capsule successive administrations 6 months, the rat mental status, autonomic activities Non Apparent Abnormality, the high dose group food ration reduces to some extent, but it is all normal that rat body weight increases, with blank group there was no significant difference (P > 0.05) relatively, point out long-time this medicine of heavy dose of gavage, may affect the rat food ration, but growth promoter (body weight gain) avirulence of rat is affected.After drug withdrawal, it is normal that the rat food ration is recovered.
Three flavor capsule successive administrations 3 months and 6 months, each dosage group P of Rats T obviously extends, and is dosage～reaction relation, and drug withdrawal recovers normal after 4 weeks, points out this medicine influential to blood coagulation system, and this is consistent with the pharmacodynamic action of this medicine.
Three flavor capsule successive administrations 6 months, high dose group rat chlorine ion concentration reduces, and drug withdrawal recovers normal after 4 weeks, points out this medicine may be influential to the chloride ion metabolism, can recover after drug withdrawal.High dose group male rat AST, CK obviously reduce (P<0.01), though drug withdrawal made moderate progress after 4 weeks (P<0.05), but still can not recover normal, point out this medicine may be influential to the buck myocardium enzyme, be not enough in 4 weeks of drug withdrawal recover, suggestion should be strengthened the monitoring to these indexs in clinical trial.
Three flavor capsule successive administrations 3 months, 6 months and after 4 weeks of drug withdrawal, gross necropsy main organs outward appearance and tangent plane, be showed no obvious pathological changes, each organ coefficient, without obvious change, is fixed through 10% formalin, the film-making of drawing materials of pathology routine, HE dyeing, observe under light microscopic, and the histological examination result shows, each organs and tissues of blank group rat is without abnormal Histological change, and each organs and tissues of administration high dose group rat is learned and changed without drug-induced abnormal structure.
Conclusion: three flavor Capsules on Rats gastric infusion safe doses are below 2.90g crude drug/kg, are about 61.70 times (adult presses the 60kg weighing machine) that clinical adult intends consumption.
The present invention---the healing case of three flavor blood circulation promoting and blood stasis dispelling capsules
Case one-Huang * *: identification card number: 2310031938 * * * * 1621;
Date of the onset: in July, 2006;
Case diagnosis: left large and small lower limb, deep venous thrombosis;
Body surface needle-like: morbidity lower limb and normal lower limb are nearlyer 50% than large, edema of lower limbs, pain;
Therapeutic scheme: drop was stopped using after urokinase on the 2nd, changed and took this product;
Taking dose: every day 3 times, each 3, after taking 1 month, body surface is tending towards normally, takes after 3 months and cures, and now by the prophylactic treatment consumption, takes this medicine every day, takes continuously 7 years, more not morbidity.
Case two---Zhao * *: identification card number: 2301031995 * * * * 0066;
Date of the onset: in January, 2009;
Case diagnosis: except non-ossifying fibroma, chondroma;
The body surface symptom: shank obviously has projection, and pain is arranged.
Therapeutic scheme: take this product;
Taking dose: first month is every day 3 times, and each 2, the dosage of taking after one month is every day 2 times, each 2, after 2 months, cures drug withdrawal.
Claims (9)
1. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules, is characterized in that, by weight, comprises the following steps:
(1), get 300～700 parts of Radix Salviae Miltiorrhizaes, add 12～24 times, water amount and extract, filter, be concentrated into the clear paste of relative density 1.0～1.5, add 2.4～4.8 times of amounts of ethanol, stir, standing 24～72 hours, get supernatant, reclaim ethanol and be dried to dry, porphyrize, standby;
(2), each 80～120 parts of water intaking trematodiasis, Pheretimas add respectively 1～10 times of amount normal saline and soak, and is ground into homogenate, freezes molten extraction, filters or centrifugal filtrate for later use; The residue extracting in water, filter, and filtrate merges with supernatant, and the ultrafilter membrane filtration is concentrated into the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirs, and is dried to dryly, and porphyrize is standby; The medical material residue soaked 1～10 day by 1～8 times of amount of ethanol again, filtered, and filtrate is concentrated into the thick paste of relative density 1.2～1.8, and viscosity reduction is thick, stirs, be dried to dry, porphyrize, standby;
(3), Radix Salviae Miltiorrhizae, Pheretima, Hirudo extract are merged, add 2～10 parts of micropowder silica gels, add starch to make into 200～400 parts, stir, incapsulate, obtain.
2. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (1), extracting in water is 2 times, adds 6～12 times of amounts of water at every turn, extracts 1～5 hour.
3. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, the ethanol described in step (1) is for adding 1～6 times of amount of 80% ethanol.
4. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (1), mixing time is 10～50 minutes.
5. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (2), Hirudo, Pheretima add respectively the immersion of 1～10 times of amount normal saline, continue and add 2 times of amounts of normal saline, are ground into homogenate.
6. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, in step (2), be ground into homogenate after jolting extracted 1～12 hour.
7. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, step is frozen molten extraction in (2), standing 1～12 hour.
8. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, the middle residue of step (2) adds 1～5 times of amount of water and extracts respectively 2 times, each 1～3 hour.
9. the preparation method of three flavor blood circulation promoting and blood stasis dispelling capsules as claimed in claim 1, is characterized in that, step (2) Chinese crude drug residue is measured lixiviate 1～10 day with 1～8 times of 50% ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310348295.7A CN103405501B (en) | 2013-08-12 | 2013-08-12 | Preparation method of three-component blood-activating and stasis-dissolving capsules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310348295.7A CN103405501B (en) | 2013-08-12 | 2013-08-12 | Preparation method of three-component blood-activating and stasis-dissolving capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103405501A true CN103405501A (en) | 2013-11-27 |
| CN103405501B CN103405501B (en) | 2015-04-22 |
Family
ID=49598575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310348295.7A Active CN103405501B (en) | 2013-08-12 | 2013-08-12 | Preparation method of three-component blood-activating and stasis-dissolving capsules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405501B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483635A (en) * | 2019-08-23 | 2019-11-22 | 王世生 | Induce liquid and preparation method thereof and hirudin/Lumbrokinase extracting method and hirudin Lumbrokinase oral solution and its preparation method and application |
| CN111481601A (en) * | 2020-04-15 | 2020-08-04 | 湖南省中医药研究院 | Medicine for treating cerebral apoplexy and construction method of endogenous stem cell expression animal model |
| CN112656883A (en) * | 2020-12-21 | 2021-04-16 | 黑龙江儒泰科技发展有限责任公司 | Blood-activating traditional Chinese medicine composition and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1281719A (en) * | 1999-07-26 | 2001-01-31 | 王淑清 | Chinese medicine composition for curing ischemic angiocardiopathy and cerebrovascular disease and its preparation method |
| CN1686289A (en) * | 2005-03-01 | 2005-10-26 | 中国人民解放军第四军医大学药物研究所 | Compound formula earthworm capsule and its preparation technology |
| CN101095697A (en) * | 2006-06-28 | 2008-01-02 | 李振国 | Extractive of bdella and/or lumbricus with the molecular weight below 5800 dalton |
| CN102178697A (en) * | 2011-04-26 | 2011-09-14 | 李双阳 | Compound leech capsule and preparation method thereof |
-
2013
- 2013-08-12 CN CN201310348295.7A patent/CN103405501B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1281719A (en) * | 1999-07-26 | 2001-01-31 | 王淑清 | Chinese medicine composition for curing ischemic angiocardiopathy and cerebrovascular disease and its preparation method |
| CN1686289A (en) * | 2005-03-01 | 2005-10-26 | 中国人民解放军第四军医大学药物研究所 | Compound formula earthworm capsule and its preparation technology |
| CN101095697A (en) * | 2006-06-28 | 2008-01-02 | 李振国 | Extractive of bdella and/or lumbricus with the molecular weight below 5800 dalton |
| CN102178697A (en) * | 2011-04-26 | 2011-09-14 | 李双阳 | Compound leech capsule and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 吴云虎 等: "丹参水蛭胶囊配合西医治疗颈动脉血管支架成形术后再狭窄46例", 《陕西中医》 * |
| 熊筱娟 等: "活血化瘀中药治疗心脑血管疾病的药理作用与临床应用", 《宜春学院学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483635A (en) * | 2019-08-23 | 2019-11-22 | 王世生 | Induce liquid and preparation method thereof and hirudin/Lumbrokinase extracting method and hirudin Lumbrokinase oral solution and its preparation method and application |
| CN111481601A (en) * | 2020-04-15 | 2020-08-04 | 湖南省中医药研究院 | Medicine for treating cerebral apoplexy and construction method of endogenous stem cell expression animal model |
| CN112656883A (en) * | 2020-12-21 | 2021-04-16 | 黑龙江儒泰科技发展有限责任公司 | Blood-activating traditional Chinese medicine composition and application thereof |
| CN112656883B (en) * | 2020-12-21 | 2022-01-28 | 黑龙江儒泰科技发展有限责任公司 | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103405501B (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600423B (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN102772748B (en) | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN103893283B (en) | A kind of Chinese medicine composition for treating chronic kidney disease and chronic kidney hypofunction and preparation method thereof | |
| CN105343466A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN101849987A (en) | Preparation of Chinese angelica and astragalus root mixture ethanol extract and aqueous extract and application in intervening in pulmonary fibrosis | |
| CN110123854B (en) | An anti-inflammatory active pharmaceutical composition based on components of Bupleurum chinensis and its application | |
| CN101822729B (en) | Medicine for treating slow arrhythmia sick sinus syndromes | |
| CN102885307A (en) | Composition for damp-heat constitutions, preparation method and applications thereof | |
| CN100563647C (en) | The Pharmaceutical composition of Herba Erigerontis and sodium tanshinon IIA silate injection | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN101549066B (en) | Prescription for treating allergy purpura and method for preparing same | |
| CN101062027B (en) | Taurine and medical combination for treating cardiovascular and cerebrovascular diseases | |
| CN103893286B (en) | It is a kind of to treat Chinese medicine preparation of chronic renal disease and preparation method thereof | |
| CN103549072B (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN103012560B (en) | Preparation method of cyclic peptide compound from cortex lycii radicis | |
| CN102228596B (en) | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris | |
| CN1899352B (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN105535890B (en) | A kind of pharmaceutical composition and preparation method thereof for treating cardiovascular disease | |
| CN105287755A (en) | Traditional Chinese medicinal composition for treating sepsis myocardial dysfunction | |
| CN104587047B (en) | A kind of Chinese medicine composition for being used to treat cardiovascular and cerebrovascular disease | |
| CN103238834A (en) | Composition for treating cutaneous pruritus and preparation method of composition | |
| CN108743654B (en) | A kind of traditional Chinese medicine composition for treating ischemic heart disease and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |